Eledon Pharmaceuticals (NASDAQ:ELDN) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN) announced its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02), Zacks reports.

Eledon Pharmaceuticals Price Performance

Shares of NASDAQ ELDN traded down $0.56 during midday trading on Wednesday, reaching $4.26. 352,524 shares of the company traded hands, compared to its average volume of 195,346. Eledon Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $5.54. The stock has a 50-day moving average price of $3.17 and a 200 day moving average price of $2.86. The company has a market cap of $168.95 million, a price-to-earnings ratio of -2.09 and a beta of 0.76.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).